New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
13:08 EDTINSYInsys Therapeutics weakness a buying opportunity, says JMP Securities
JMP Securities said Insys Therapeutics (INSY) is weak on concerns that Subsys may be added to Express Scripts' (ESRX) exclusion list in 2015. The analyst does not know if it will or not be added but said the potential impact would not be material to sales or growth because the product is not included in any PBM preferred formula positions and has prior authorization requirements. The analyst would use weakness as a buying opportunity and reiterates its Outperform rating and $65 price target.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
08:19 EDTINSYInsys Therapeutics receives FDA ODD for CBD candidate
Insys Therapeutics announced that the FDA has granted orphan drug designation to its pharmaceutical cannabidiol, or CBD, candidate for the treatment of infantile spasms, or IS. Insys expects that its new, DEA-inspected facility in Round Rock, Texas, will enable it to manufacture ample quantities of CBD for its research and commercial plans.
July 24, 2015
16:47 EDTINSYInsys Therapeutics treatment of infantile spasms receives FDA orphan designation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use